Carcinoid/Neuroendocrine Cancer Specialist Announces Retirement from Medical Practice

October 15, 2016

Dr. Richard R.P. Warner, Director of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai Hospital, has announced that he is retiring from his medical practice at Mount Sinai, as of November 1, 2016. Read more

READ MORE

Stanford Health Care in California Launches Neuroendocrine Tumor Multidisciplinary Program

August 14, 2016

A new multidisciplinary Neuroendocrine Cancer center at Stanford Health Care in California has been established to improve the standard of care for NET patients and to advance the study of these rare diseases. Pamela Kunz, MD, is the Medical Director…

READ MORE

Carcinoid Cancer Foundation Announces Appointment of Edward M. Wolin, MD as Co-Medical Director and Board Member

June 24, 2016

Edward M. Wolin, MD, an internationally renowned neuroendocrine cancer specialist and medical oncologist, has been named Co-Medical Director and Board member of the Carcinoid Cancer Foundation (CCF) in White Plains, New York.  Dr. Wolin is Director

READ MORE

FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors

June 1, 2016

Breaking news on June 1, 2016 from the U.S. Food and Drug Administration! The FDA has approved NETSPOT, “the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.”…

READ MORE

FDA Priority Review of Lexicon’s New Drug Application for Telotristat Etiprate Treatment for Carcinoid Syndrome

May 31, 2016

Lexicon Pharmaceuticals announced on May 31, 2016 that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of CARCINOID SYNDROME. “The FDA has granted…

READ MORE

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

April 29, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration during the week of April 25, 2016, a decision from the FDA is expected in early 2017.…

READ MORE

Ipsen Partners with CCF and Self Care Catalysts to Provide Free Support App for Neuroendocrine Tumor Patients

April 6, 2016

Ipsen Biopharmaceuticals has partnered with the Carcinoid Cancer Foundation and Self Care Catalysts to provide a digital patient support tool known as the Carcinoid NETs Health Storylines mobile and web application. Sponsored in part by Ipsen, the…

READ MORE

Lexicon Pharmaceuticals Submits New Drug Application for Telotristat Etiprate

April 3, 2016

Lexicon Pharmaceuticals has submitted a new drug application to the US Food and Drug Administration (FDA) for Telotristat Etiprate for the treatment of carcinoid syndrome.

For patients with carcinoid syndrome who are no longer responding to the current…

READ MORE

Breaking News about PRRT

March 23, 2016

Advanced Accelerator Applications (AAA) announced  on March 23, 2016 that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program Lutathera is being made available…

READ MORE

Finding an Outlet in the Face of Rare Cancers by Diane Reidy Lagunes, MD

March 16, 2016

Carcinoid/neuroendocrine cancer specialist Dr. Diane Reidy Lagunes, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, explains how her patients inspire her as a physician and why she participates in Cycle for Survival

READ MORE